文章摘要
陶 珍,陈 蕾,程 明,唐吉刚,郭洪伟.吡拉西坦联合鼠神经生长因子对急性缺血性脑卒中患者的疗效及Hcy、PCT和皮质醇水平的影响[J].,2020,(10):1944-1948
吡拉西坦联合鼠神经生长因子对急性缺血性脑卒中患者的疗效及Hcy、PCT和皮质醇水平的影响
Efficacy of Piracetam Plus Rat Nerve Growth Factor on Patients with Acute Ischemic Stroke and Its Effects on Hcy, PCT and Cortisol Levels
投稿时间:2019-11-23  修订日期:2019-12-18
DOI:10.13241/j.cnki.pmb.2020.10.032
中文关键词: 急性缺血性脑卒中  吡拉西坦  鼠神经生长因子  同型半胱氨酸  降钙素原  皮质醇
英文关键词: Acute ischemic stroke  Piracetam  Rat nerve growth factor  Homocysteine  Procalcitonin  Cortisol
基金项目:
作者单位E-mail
陶 珍 海军第971医院神经内科 山东 青岛 266071 1367498775@qq.com 
陈 蕾 海军军医大学附属长海医院神经内科 上海 200433  
程 明 中国人民解放军联勤保障部队第960医院神经内科 山东 济南 250031  
唐吉刚 中国人民解放军联勤保障部队第960医院神经内科 山东 济南 250031  
郭洪伟 中国人民解放军联勤保障部队第960医院神经内科 山东 济南 250031  
摘要点击次数: 733
全文下载次数: 456
中文摘要:
      摘要 目的:探讨吡拉西坦联合鼠神经生长因子对急性缺血性脑卒中患者的疗效及对同型半胱氨酸(Hcy)、降钙素原(PCT)和皮质醇水平的影响。方法:回顾性分析我院2017年2月~2018年11月收治的73例急性缺血性脑卒中患者为研究对象,依据入院先后顺序分为对照组(n=35)和观察组(n=38)。对照组患者采用吡拉西坦治疗,观察组基于对照组加以鼠神经生长因子治疗。观察并比较两组临床疗效,治疗前后美国国立卫生研究院卒中量表(NIHSS)、日常生活能力(ADL),治疗前及治疗2周结束时用全自动生化分析仪测定血浆Hcy水平,用放射免疫学分析法测定PCT水平,用化学发光法测定皮质醇水平,用超声多普勒诊断仪测定基底动脉、左右大脑中动脉血流。结果:治疗后,观察组NIHSS评分低于对照组(8.96±1.21)vs(11.27±1.59)分,ADL评分高于对照组(74.21±9.75)vs(66. 04±8.03)分(P<0.05)。观察组总有效率高于对照组89.47% vs 68.57%(P<0.05)。治疗后,观察组Hcy、PCT及皮质醇水平低于对照组(14.27±2.01)vs(18.51±2.84)μmol/L、(0.25±0.03)vs(0.31±0.04)μg/L、(171.93±23.86)vs(228.75±30.27)nmol/L(P<0.05)。治疗后,观察组脑血流学指标高于对照组基底动脉(43.81±6.84)vs(39.62±5.27)mL/min、左大脑中动脉血流(64.27±9.95)vs(57.03±7.52)mL/min、右大脑中动脉血流(62.85±9.01)vs(56.64±7.42)mL/min(P<0.05)。结论:吡拉西坦联合鼠神经生长因子能够提高急性缺血性脑卒中的疗效,降低Hcy、PCT及皮质醇水平,促进神经功能的恢复。
英文摘要:
      ABSTRACT Objective: To investigate efficacy of piracetam combined with rat nerve growth factor on patients with acute ischemic stroke and its effect on homocysteine (Hcy), procalcitonin (PCT) and cortisol levels. Methods: 73 patients with acute ischemic stroke admitted to our hospital from February 2017 to November 2018 were analyzed retrospectively. They were divided into the control group (n=35) and the observation group (n=38) according to the order of admission. Patients in the control group were treated with piracetam, while patients in the observation group were treated with rat nerve growth factor based on the control group. The clinical efficiency, national institutes of health stroke scale (NIHSS), activity of daily living (ADL), before treatment and at the end of 2 weeks of treatment, plasma Hcy level was measured with automatic biochemical analyzer, PCT level was measured with radioimmunoassay, cortisol level was measured with chemiluminescence method, and blood flow of basilar artery and left and right middle cerebral arteries was measured with ultrasonic Doppler diagnostic instrument. Results: The total effective rate of the observation group was higher than that of the control group 89.47% vs 68.57%, the difference was statistically significant (P<0.05). After treatment, the NIHSS score of the observation group was lower than that of the control group (8.96±1.21) vs (11.27±1.59)points, and the ADL score was higher than that of the control group (74.21±9.75) vs (66.04±8.03)points, the difference was statistically significant (P<0.05). After treatment, the levels of Hcy, PCT and cortisol in the observation group were lower than those in the control group (14.27±2.01) vs (18.51±2.84) μmoL/L, (0.25±0.03) vs (0.31±0.04) μg/L, (171.93±23.86) vs (228.75±30.27) nmoL/L, the difference was statistically significant (P<0.05). After treatment, the cerebral blood flow indexes in the observation group were higher than those in the control group (43.81±6.84) vs (39.62±5.27) mL/min, left middle cerebral artery blood flow (64.27±9.95) vs (57.03±7.52) mL/min, right middle cerebral artery blood flow (62.85±9.01) vs (56.64±7.42) mL/min, the difference was statistically significant (P<0.05). Conclusion: Piracetam plus rat nerve growth factor can improve the curative effect of acute ischemic stroke, reduce the levels of Hcy, PCT, cortisol, and promote the recovery of nerve function.
查看全文   查看/发表评论  下载PDF阅读器
关闭